-
Je něco špatně v tomto záznamu ?
Anterior gradient protein 3 is associated with less aggressive tumors and better outcome of breast cancer patients
J. Obacz, V. Brychtova, J. Podhorec, P. Fabian, P. Dobes, B. Vojtesek, R. Hrstka,
Jazyk angličtina Země Nový Zéland
Typ dokumentu časopisecké články
Grantová podpora
NT13794
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
Zdroj
NLK
Directory of Open Access Journals
od 2008
Free Medical Journals
od 2008
PubMed Central
od 2008
Europe PubMed Central
od 2008
ProQuest Central
od 2015-01-01
Open Access Digital Library
od 2008-01-01
Open Access Digital Library
od 2008-01-01
Taylor & Francis Open Access
od 2008-12-01
Health & Medicine (ProQuest)
od 2015-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2008
PubMed
26170690
DOI
10.2147/ott.s82235
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
Anterior gradient protein (AGR) 3 is a highly related homologue of pro-oncogenic AGR2 and belongs to the family of protein disulfide isomerases. Although AGR3 was found in breast, ovary, prostate, and liver cancer, it remains of yet poorly defined function in tumorigenesis. This study aimed to determine AGR3 expression in a cohort of 129 primary breast carcinomas and evaluate the clinical and prognostic significance of AGR3 in these tumors. The immunohistochemical analysis revealed the presence of AGR3 staining to varying degrees in 80% of analyzed specimens. The percentage of AGR3-positive cells significantly correlated with estrogen receptor, progesterone receptor (both P<0.0001) as well as low histological grade (P=0.003), and inversely correlated with the level of Ki-67 expression (P<0.0001). In the whole cohort, AGR3 expression was associated with longer progression-free survival (PFS), whereas AGR3-positive subgroup of low-histological grade tumors showed both significantly longer PFS and overall survival. In conclusion, AGR3 is associated with the level of differentiation, slowly proliferating tumors, and more favorable prognosis of breast cancer patients.
Department of Pathology Masaryk Memorial Cancer Institute Brno Czech Republic
Regional Centre for Applied Molecular Oncology Brno Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15031291
- 003
- CZ-PrNML
- 005
- 20191021135409.0
- 007
- ta
- 008
- 151005s2015 nz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2147/OTT.S82235 $2 doi
- 035 __
- $a (PubMed)26170690
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a nz
- 100 1_
- $a Obacz, Joanna $u Regional Centre for Applied Molecular Oncology (RECAMO), Brno, Czech Republic.
- 245 10
- $a Anterior gradient protein 3 is associated with less aggressive tumors and better outcome of breast cancer patients / $c J. Obacz, V. Brychtova, J. Podhorec, P. Fabian, P. Dobes, B. Vojtesek, R. Hrstka,
- 520 9_
- $a Anterior gradient protein (AGR) 3 is a highly related homologue of pro-oncogenic AGR2 and belongs to the family of protein disulfide isomerases. Although AGR3 was found in breast, ovary, prostate, and liver cancer, it remains of yet poorly defined function in tumorigenesis. This study aimed to determine AGR3 expression in a cohort of 129 primary breast carcinomas and evaluate the clinical and prognostic significance of AGR3 in these tumors. The immunohistochemical analysis revealed the presence of AGR3 staining to varying degrees in 80% of analyzed specimens. The percentage of AGR3-positive cells significantly correlated with estrogen receptor, progesterone receptor (both P<0.0001) as well as low histological grade (P=0.003), and inversely correlated with the level of Ki-67 expression (P<0.0001). In the whole cohort, AGR3 expression was associated with longer progression-free survival (PFS), whereas AGR3-positive subgroup of low-histological grade tumors showed both significantly longer PFS and overall survival. In conclusion, AGR3 is associated with the level of differentiation, slowly proliferating tumors, and more favorable prognosis of breast cancer patients.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Brychtová, Veronika $u Regional Centre for Applied Molecular Oncology (RECAMO), Brno, Czech Republic. $7 xx0228678
- 700 1_
- $a Podhorec, Ján $u Regional Centre for Applied Molecular Oncology (RECAMO), Brno, Czech Republic. $7 xx0171899
- 700 1_
- $a Fabian, Pavel $u Department of Pathology, Masaryk Memorial Cancer Institute, Brno, Czech Republic. $7 xx0041823
- 700 1_
- $a Dobeš, Petr $u Regional Centre for Applied Molecular Oncology (RECAMO), Brno, Czech Republic. $7 _AN051505
- 700 1_
- $a Vojtěšek, Bořivoj, $u Regional Centre for Applied Molecular Oncology (RECAMO), Brno, Czech Republic. $d 1960- $7 xx0001694
- 700 1_
- $a Hrstka, Roman $u Regional Centre for Applied Molecular Oncology (RECAMO), Brno, Czech Republic. $7 xx0077297
- 773 0_
- $w MED00165461 $t OncoTargets and therapy $x 1178-6930 $g Roč. 8, č. - (2015), s. 1523-1532
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26170690 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20151005 $b ABA008
- 991 __
- $a 20191021135842 $b ABA008
- 999 __
- $a ind $b bmc $g 1092167 $s 914417
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 8 $c - $d 1523-1532 $e 20150624 $i 1178-6930 $m OncoTargets and therapy $n OncoTargets ther. $x MED00165461
- GRA __
- $a NT13794 $p MZ0
- LZP __
- $a Pubmed-20151005